Researchers found that mice that received the new Tetra Therapeutics drug BPN14770 had reduced activity of the phosphodiesterase-4D enzyme in the brain, prompting elevated cyclic adenosine monophosphate signaling linked to protection against the adverse effects of amyloid-beta proteins associated with Alzheimer's disease. The findings in the Journal of Pharmacology and Experimental Therapeutics suggest that BPN14770 may not only be used in treating Alzheimer's disease and dementia but also Fragile X syndrome, schizophrenia and developmental disabilities.
Study evaluates potential breakthrough drug for Alzheimer's disease
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.